“The findings suggest that lifetime classic psychedelic use is associated with lower odds of having had heart disease or diabetes in the past year,” lead study author and Oxford sociologist Otto Simonsson, [said]. A team of scientists identified the unexpected trend after poring over ten years’ worth of data from the National Survey on Drug…
The future of psychedelic therapy is also uncertain. While it seems likely that at least some psychedelic drugs will be approved for certain medical conditions in the years to come, it’s also possible that recreational use could be widely decriminalized or legalized. The status quo could also stay in place. The companies and people hoping…
Across a wide range of body weights (49kg [approx. 108lbs] to 113 kg [approx. 249lbs]) the present results showed no evidence that body weight affected subjective effects of psilocybin. In the 20 mg/70 kg and 30 mg/70 kg weight-adjusted groups, and in the fixed dose group, no significant associations were found between subjective effects and demographic variables including body weight…
For those… who grew up in the “this is your brain on drugs” era, it’s hard to let go of stigma – and the mental image of an egg sizzling on a hot pan. But as a growing number of states and cities move to decriminalize… Healing the healers is a win-win, and everyone can…
Citing the medical benefits of psilocybin, nine U.S. cities and the State of Oregon have decriminalized or legalized psilocybin… In Oregon, the Research Subcommittee of the Oregon Psilocybin Advisory Board, composed of physicians, biologists and public health officials, analyzed the research and concluded that “high quality phase [I and II] clinical trials suggest that psilocybin is efficacious…
…the authors of the new study claim to have developed an extremely cheap method of producing psilocybin… “In less than [two] days, we successfully produced approximately 300 mg/L of psilocybin under simple conditions with easily sourced equipment and supplies,” write the study authors. “This work demonstrates the biosynthesis of psilocybin at concentrations in the 100s…
Grant Project 5R01MH084894-12: Our published data and the preliminary data presented here support our working hypothesis that inter-family GPCR heteromerization affects structure, sub-cellular localization and function of both 5-HT2AR and mGluR2 in living mammalian cells. Our data are also consonant with the hypothesis that a single dose of hallucinogenic 5-HT2AR agonists induces fast-acting and long-lasting…
Funding from the National Institute of Health [NIH], which tends to award larger grants than philanthropists, allows researchers to delve more into the details, Johnson says. Grant Project Number 1K23MH122777-01A1: We hypothesize that psilocybin will result in increased (i.e. normalized) intra-DMN functional connectivity in OCD, and that this will correlate with any clinical change (Aim 1). Baseline…
“The funding side of the government has been the last to the party for a long time,” says Matthew Johnson, who studies psychedelics at Johns Hopkins University. Grant Project Number 1U01DA052174-01A1: We hypothesize that psilocybin (compared to niacin) will cause increased biologically-confirmed 7-day point-prevalence abstinence at 12-month follow-up. Based on pilot data, we will test cognitive/psychological mediators…
“The funding side of the government has been the last to the party for a long time,” says Matthew Johnson, who studies psychedelics at Johns Hopkins University. Grant Project Number 1U01DA052174-01A1: We hypothesize that psilocybin (compared to niacin) will cause increased biologically-confirmed 7-day point-prevalence abstinence at 12-month follow-up. Based on pilot data, we will test cognitive/psychological mediators…
